Bond.az White LogoBond.az Black Logo

Vallourec Q1 2026 Beats Forecasts, Stock Fluctuates

Vallourec Q1 2026 earnings beat forecasts; stock sees volatility. Strong EBITDA and cash flow highlight performance.

Sophia Anderson
BySophia Anderson- Senior Editor
|
0

Vallourec reported Q1 2026 earnings that surpassed expectations, with EPS of $0.35 vs. forecast $0.338, a 3.55% surprise. Revenue came in at $975 million, exceeding the expected $913.32 million. The stock initially surged 13.23% to $27.465, then dropped 8.59% to $26.365, reflecting mixed investor sentiment.

Group EBITDA reached $220 million, with margin improvement of 200 basis points to 22.6%. Tubes segment EBITDA per ton hit $724, driven by favorable mix and cost management. The company generated strong cash flow and increased net cash to $67 million after $107 million in share buybacks.

Looking ahead, Vallourec expects Q2 EBITDA between $175-205 million, with improvements in H2. The company is optimistic about U.S. pricing and international tendering activity, particularly in offshore and new energy sectors.

More News
Today / 14:20
|
888

Home Depot Q1 2026 earnings beat forecasts, stock dips

Home Depot Q1 2026 earnings beat forecasts with EPS of $3.43 and revenue of $41.8B. Stock dips 2.49% amid margin concerns.

0
Today / 14:03
|
352

Hera Group Q1 2026: Steady growth

Hera Group posts steady growth in Q1 2026 with net profit of EUR 155 million and EPS of $0.105.

0
Today / 14:02
|
259

Oxford Lane Capital NAV drops, stock dips

Oxford Lane Capital Corp reports Q4 FY2026 results: NAV per share down, stock falls 4.03%. CLO yields decline. Read more on challenges and outlook.

0
Today / 13:43
|
246

Driven Brands Q4 2025 Revenue Growth Reported

Driven Brands Q4 2025 revenue grows 7.7% to $460.1M, EPS $0.34. Stock up 1.12%.

0
Today / 13:41
|
777

Ceragon Q1 2026 Revenue Beats Estimates

Ceragon Networks Q1 2026 revenue beat estimates at $85M. EPS $0.01. Stock rose 6.77% premarket. Full-year guidance reiterated.

0
Today / 13:10
|
739

Fractyl Health Q1 2026 EPS Beat, Shares Surge 23%

Fractyl Health Q1 2026 EPS beat expectations by 76%, shares surged 23% after hours. Revita program data expected in Q4 2026.

0
Today / 13:01
|
272

Antalpha Q1 2026: EPS Misses Forecast, Stock Rises

Antalpha Q1 2026: EPS misses forecast at $0.07, stock rises 2.42%. Revenue up 52% to $20.7M. Web3 AI agent Nina launched. Q2 guidance $11M-$13M.

0
Today / 12:44
|
314

GNFC Q4 profit surges, stock climbs 5.17%

GNFC Q4 FY2026 strong results: revenue up 11%, PAT up 35%, stock rises 5.17%. Chemical segment drives growth.

0
Today / 12:42
|
677

Relmada TX Q1 2026: Loss and stock dip

Relmada Therapeutics Q1 2026 results: stock declines, strong cash position and NDV-01 program in focus.

0
Today / 12:00
|
959

Inovio Beats Q1 2026 EPS Forecast, Stock Slips

Inovio Q1 2026 EPS beats forecasts, but stock falls. Detailed financial analysis and outlook on Bond.az.

0
Today / 11:50
|
449

CytoSorbents Q1 2026 Misses Forecasts, Stock Falls

CytoSorbents Q1 2026 results: EPS of -$0.05 misses estimate, revenue of $8.9M falls short, stock drops 7.53%. Company cuts costs and targets breakeven in H2 2026.

0
Today / 10:53
|
859

IOC Q4 2026 earnings beat expectations

IOC Q4 2026 earnings beat expectations with EPS of 6.15, a 20.59% surprise. Stock rose 2.42%. Record refining throughput and 184% profit growth reported.

0
...